Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose

Citation for published version:
Laurent, D, Semple, F, Starkey Lewis, PJ, Rose, E, Black, HA, Coe, J, Forbes, SJ, Arends, MJ, Dear, JW & Aitman, TJ 2020, 'Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose', Journal Title BMC Medical Genomics, vol. 13, 60 (2020). https://doi.org/10.1186/s12920-020-0705-2

Digital Object Identifier (DOI):
10.1186/s12920-020-0705-2

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal Title BMC Medical Genomics

Publisher Rights Statement:
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose

Danny Laurent, Fiona Semple, Philip J. Starkey Lewis, Elaine Rose, Holly A. Black, Jennifer Coe, Stuart J. Forbes, Mark J. Arends, James W. Dear and Timothy J. Aitman

Abstract

Background: Despite the emergence of cell-free DNA (cfDNA) as a clinical biomarker in cancer, the tissue origins of cfDNA in healthy individuals have to date been inferred only by indirect and relative measurement methods, such as tissue-specific methylation and nucleosomal profiling.

Methods: We performed the first direct, absolute measurement of the tissue origins of cfDNA, using tissue-specific knockout mouse strains, in both healthy mice and following paracetamol (APAP) overdose. We then investigated the utility of total cfDNA and the percentage of liver-specific cfDNA as clinical biomarkers in patients presenting with APAP overdose.

Results: Analysis of cfDNA from healthy tissue-specific knockout mice showed that cfDNA originates predominantly from white and red blood cell lineages, with minor contribution from hepatocytes, and no detectable contribution from skeletal and cardiac muscle. Following APAP overdose in mice, total plasma cfDNA and the percentage fraction originating from hepatocytes increased by ~100 and ~19-fold respectively. Total cfDNA increased by an average of more than 236-fold in clinical samples from APAP overdose patients with biochemical evidence of liver injury, and 18-fold in patients without biochemically apparent liver injury. Measurement of liver-specific cfDNA, using droplet digital PCR and methylation analysis, revealed that the contribution of liver to cfDNA was increased by an average of 175-fold in APAP overdose patients with biochemically apparent liver injury compared to healthy subjects, but was not increased in overdose patients with normal liver function tests.

Conclusions: We present a novel method for measurement of the tissue origins of cfDNA in healthy and disease states and demonstrate the potential of cfDNA as a clinical biomarker in APAP overdose.

Keywords: Cell-free DNA, Origin, Absolute, APAP

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
In 1948, Mandel and Metaïs described the presence of DNA in plasma [1], now known as cell-free DNA (cfDNA) and known to be present in other bodily fluids, such as urine [2], saliva and cerebrospinal fluid [3]. Release of cfDNA into the circulation is likely due to cellular breakdown mechanisms, such as apoptosis and necrosis, as well as active DNA release mechanisms [4]. The size profile of cfDNA typically follows multiples of the ~180 bp nucleosomal unit [5, 6], with a dominant peak size of 167 bp [7].

Analysis of cfDNA is clinically useful for detecting genetic and epigenetic alterations in DNA by allowing repeated non-invasive or minimally invasive sampling from bodily fluids [8]. Analysis of foetal cfDNA in maternal plasma has been clinically implemented for non-invasive prenatal testing of chromosomal abnormalities and some monogenic disorders [9, 10]. Analysis of cfDNA in cancer genomics is evolving rapidly [11–14] and utility of cfDNA as a biomarker of internal tissue damage [15–17], in organ transplantation [18] and in autoimmune disease is being investigated [19, 20].

Despite these developments, the tissue origins of cfDNA are not yet completely known. Current understanding rests on indirect and relative measurement methods, such as tissue-specific methylation markers [21–23] and nucleosomal profiling [7], with substantial variations in the estimated proportions of the tissues of origin between different studies [24]. Here, we present the first absolute, direct measurement of the tissue origins of cfDNA using six tissue-specific knockout mice. cfDNA originating from healthy mice was achieved by analysing cfDNA from tissue samples collected from mice post-mortem and stored at ~70 °C prior to analysis.

Induction of APAP overdose in mice
Mice were fasted 12 h prior to intraperitoneal (IP) injection with APAP (350 mg/kg mouse body weight), maintained in a 30 °C incubator and given semi-solid food. Experiments were carried out under the Home Office project license PPL 70/7847. To investigate the timepoint where cfDNA concentration is highest following APAP overdose, culling and plasma collection were performed at 8, 24 and 48 h following APAP injection in C57BL/6 mice (Charles River Laboratories, UK; n = 4 per time point).

Methods
Generation of tissue-specific knockout mice
Absolute measurement of the tissue origins of cfDNA in healthy mice was achieved by analysing cfDNA from tissue-specific knockout mice. cfDNA originating from the cells of interest, which express Cre recombinase from a cell-specific promoter, were recombined (1lox), as opposed to unrec combined (2lox) from other cell types in the body that do not express Cre recombinase (Additional File 1: Figure S1). For this study, a conditional mutation in the floxed mT/mG dual reporter gene [25] was generated in C57BL/6 mice by crossing mice homozygous for the floxed mT/mG gene with mice expressing different cell/tissue-specific Cre recombinase to obtain cell/tissue-specific knockout F1 mice. Myeloid (LysMCre) [26], lymphoid (hCD2-iCre) [27], cardiomyocyte (cTnTCre) [28], hepatocyte (AlbCre) [29] and striated muscle (MCKCre) [30] Cre mice were obtained from the Jackson laboratory. Erythroid (EpoRCre) [31] mice were obtained from Prof. Stuart Orkin (Cooperative Centers of Excellence in Hematology, Bostons Children’s Hospital).

Mice breeding was carried out in individually ventilated cages (4–6 mice per cage depending on litter size) with constant access to food and water, in the Biomedical Research Facility (BRF), University of Edinburgh (UoE) under Home Office project license PPL P1070AA99 and genotyping was performed by Transnetyx (Cordova, Tennessee, USA) to confirm the presence of Cre recombinase and the floxed mT/mG gene. A total of 91 male tissuespecific knockout mice (F1, n > 10 for each knockout line, Additional File 2: Figure S2) were culled at 10–12 weeks old via exposure to gradually increasing concentrations of carbon dioxide gas (schedule 1 method) at 10% displacement rate (chamber volume / minute). Carbon dioxide flow was continued for 1–2 min after cessation of breathing. No anaesthetic agent was used in the study. Blood was collected post-mortem from the inferior vena cava using 1 ml syringes with a 25G needle into EDTA tubes. Plasma was obtained by centrifugation of blood at 1000 g for 10 min, then 16,000 g for 5 min, within 3 h of blood collection. Tissue samples were collected from mice post-mortem and stored at ~70 °C prior to analysis.
the Pathology Department, UoE, and liver function tests (alanine aminotransferase / ALT, aspartate aminotransferase/AST, albumin (ALB), bilirubin) were performed on plasma samples at the Shared University Research Facility, UoE.

**Clinical samples**

Serum was collected from healthy volunteers \( (n = 11) \) and APAP overdose patients \( (n = 8) \) from the SNAP Clinical Trial [32]. All study subjects were over the age of 16 years and gave written informed consent. The overdose group was comprised of two groups: normal ALT \( (n = 4) \) and raised ALT \( (n = 4) \), indicating clinical/biochemically apparent liver injury. Additionally, paired serum samples from three APAP overdose patients before and 20–40 h after treatment with N-acetylcysteine (NAC, 500-900 mg NAC/kg of patient body weight) were analysed to show changes in biomarker levels before and after treatment. Blood samples were centrifuged at 1000 g for 15 min at 4 °C and the supernatant was separated into aliquots and stored at −80 °C prior to analysis. The protocol was approved by the Scotland A Research Ethics Committee, UK (ref no 10/MRE00/20).

**Genomic and cell-free DNA extraction and quantitation**

Genomic DNA \( (gDNA) \) was extracted from frozen tissue samples using DNEasy blood and tissue kit (QIAGEN) and quantified using the Qubit dsDNA Broad Range assay kit (Thermo Fisher Scientific) according to manufacturer’s instructions. cfDNA was extracted from plasma using the QIAamp circulating nucleic acid kit (QIAGEN) according to the manufacturer’s instructions. cfDNA from clinical samples and mice was quantified using a single locus qPCR assay on the beta-actin \( (ACTB / Actb) \) gene [33, 34]. Fragment analysis of cfDNA was performed using Agilent DNA Bioanalyser.

**Droplet-digital PCR assay design and validation**

A probe-based droplet-digital PCR \( (ddPCR) \) assay was designed to quantify the 1lox and 2lox \( mT/mG \) alleles. The assay was adapted from a probe-based qPCR assay [35] and designed using Primer3 [36] following the Biorad ddPCR application guide, with a maximum amplicon size of 130 bp to accommodate for small fragments of cfDNA. The assay was validated by amplification of gDNA containing only 1lox or 2lox DNA fragments by ddPCR (Additional File 3: Table S1).

**Visualisation of Cre recombination with fluorescence imaging and histological analysis of tissue samples**

Fluorescence microscopy of frozen tissue sections from knockout mice was performed to visually confirm Cre recombination in tissues, based on expression of cell membrane-localised enhanced green fluorescent protein (mG) and cell membrane-localised tdTomato (mT).

Sections of 5 μm were obtained from frozen tissues using a cryostat. These sections were put on a slide with mounting medium prolong gold and DAPI to stain nuclear DNA and left overnight at 4 °C. Sectioning and staining were performed in the Pathology Department, UoE. Slides were visualised using a Biretmac epifluorescence microscope in the Institute of Genetics and Molecular Medicine (IGMM) Advanced Imaging Facility, UoE, with non-fluorescent frozen tissue slides from C57BL/6 mice as a negative control for tissue autofluorescence.

**Analysis of Cre recombination in genomic DNA and cell-free DNA**

Cre recombination was analysed in gDNA of tissue-specific knockout mice using ddPCR to ensure successful recombination in the target tissue and check for specificity of Cre recombination in non-target tissues. Analysis of Cre recombination in the cfDNA of tissue-specific knockout mice was performed to show the contribution of the corresponding Cre-driven cell/tissue types to cfDNA. An input of 10 ng of cfDNA was required for each well of ddPCR. Amplification of 1lox and 2lox alleles were performed in separate wells. Each sample was measured at least in triplicate. The amplification was run on a thermal cycler as follows: 10 min of activation at 95 °C, 40 cycles of a two-step amplification protocol (30s at 94 °C denaturation and 60s at 60 °C), and a 10-min inactivation step at 98 °C. The metric used to show Cre recombination was percentage recombination \( (1lox%) \).

\[
1lox\% = \frac{total\ 1lox\ allele}{1lox\ +\ 2lox\ allele}\ *100\%
\]

**Analysis of liver-specific methylation fragments in human cfDNA**

The contribution of liver tissue to cfDNA in clinical samples was analysed using a methylation-specific ddPCR assay [37] on bisulphite-converted cfDNA using the Epitect DNA bisulphite conversion kit (QIAGEN). The assay consisted of a mixture of primer pairs and probes (Additional File 4: Table S2) that specifically amplified a methylated \( (\text{from liver}) \) and unmethylated \( (\text{from other tissues}) \) region in the PTK2B gene (chr8: 27,183,116-27,183,176, hg19). The amplification reaction was run on a thermocycler as follows: 10 min of denaturation at 95 °C, 45 cycles of a two-step amplification protocol (94 °C for 15 s and 60 °C for 60 s), and a 10-min inactivation step at 98 °C.

**Statistics**

For the comparison of cell-free DNA in the healthy states from different tissue-specific knockout lines,
Results

Validation of ddPCR assay for absolute quantification of cfDNA tissue origins

We designed and validated a ddPCR assay to quantify recombination in the floxed mT/mG gene. Amplification of gDNA was performed to demonstrate specificity for each target allele (Fig. 1a and b). Amplification of 2lox gDNA with the 1lox assay showed no positive droplet (Fig. 1a). Amplification of the 1lox gDNA with the 2lox assay showed 13 positive droplets out of a total of 16,467 (less than 0.1%) (Fig. 1b). Assay sensitivity was tested using a dilution series of target alleles to show that the assay reproducibly quantifies less than 30 target alleles (Fig. 1c). Non-specific amplification was not observed in C57BL/6 background gDNA, nor in the water negative control.

Analysis of DNA recombination in mouse tissues

Cre recombination was confirmed in expected tissues using ddPCR (Fig. 2a) and fluorescence microscopy based on the expression of the mT/mG reporter gene (Fig. 2b). To check for specificity of Cre recombination, we performed ddPCR on gDNA extracted from 16 tissue types for each knockout line. Highest specificity was found in hepatocyte and cardiomyocyte knockout lines, where recombination was observed in liver and heart, respectively, with minimal recombination in other tissues (Fig. 2c). Specificity of Cre recombination was more variable, but generally lower in the other knockout lines (Additional File 5: Figure S3).

Tissue origins of cfDNA in healthy mice

To determine the tissue origins of cfDNA, we analysed cfDNA from the six tissue-specific knockout lines using ddPCR. Plasma from 10 or more mice for each knockout line was pooled prior to cfDNA extraction, to account for the small circulating blood volume of individual mice and the low physiological concentration of cfDNA (Additional File 6: Figure S4). Sufficient DNA was extracted for triplicate measurements of the pooled sample from each line by ddPCR (Fig. 3a). DNA fragment analysis confirmed the expected cfDNA fragment size profile which followed the mono-, di- and tri-nucleosome pattern associated with apoptosis, with larger cfDNA fragments most likely due to tissue necrosis and lysis (Fig. 3b).

Contribution of different cell types to cfDNA was quantified by counting the number of 1lox and 2lox alleles in the cfDNA of mice for each knockout line and subsequently the percentage recombination (1lox%) for each of the knockout lines was calculated (Fig. 3c). Absolute measurement of cfDNA showed that myeloid, lymphoid and erythroid lineages were the major contributors to the levels of cfDNA in healthy mice, contributing 39.7, 27.8 and 10.7% respectively, with a small contribution from hepatocytes (4.2%). Both cardiomyocyte and striated muscle cells had undetectable contribution to the levels of cfDNA (Fig. 3d). A comparison of these findings with two other studies in human using methylation pattern confirmed haematopoietic cells as major contributors to cfDNA in the healthy state (Additional File 7: Table S3).

Tissue origins of cfDNA following tissue injury in mice

To validate tissue-specific knockout mice as a model system for studying the tissue origins of cfDNA, we measured hepatocyte-specific cfDNA levels after APAP overdose in hepatocyte-specific knockout mice. The optimal timepoint for sample collection was determined using C57BL/6 mice after APAP administration. Following APAP administration, mice developed phenotypic signs of acute liver injury, characterised by hunched posture, with no severe signs of liver injury, including loss of mobility or abnormal respiration. We assayed plasma for protein biomarkers of liver function and analysed histological liver sections at 8, 24 and 48 h after administration of APAP which confirmed liver injury from 8 h after APAP administration (Additional File 8: Figure S5). Analysis of total plasma cfDNA demonstrated an increase of ~100-fold in APAP-dosed mice compared to mice receiving saline injection, which peaked at 8 h post APAP dose. cfDNA in hepatocyte-specific knockout mice was subsequently measured at 8 h, where we also observed greater than 100-fold increase in the total cfDNA following APAP dosing, compared to control mice receiving overdose patients was performed on individual samples (n = 19) in a single experiment. Non-parametric statistical methods were performed on datasets to account for small sample sizes, the presence of data outliers, and data distribution that was not normal. Normality of data distribution was confirmed using Shapiro-Wilk test. The presence of outliers in datasets were confirmed using graphical examination of boxplots. A Mann-Whitney U test were performed to compare biomarker measurements between different groups of clinical samples, and to compare percentage of recombination of the floxed mT/mG gene in mouse tissues. Statistical dependence between biomarkers in clinical samples were assessed using Spearman’s rank correlation coefficient.
saline only injections. The majority of the increase of cfDNA in mice following APAP overdose is from fragments of 170 bp as shown by fragment analysis (Additional File 9: Figure S6), indicating minimal contamination from lysed leukocytes in these samples during sample pre-processing. An increase of the liver biomarkers, ALT and AST, and histological analysis of mouse liver tissues confirmed the presence of liver injury (Fig. 4). Furthermore, quantification
of liver-specific cfDNA at 8 h post APAP dosing in hepatocyte-specific knockout mice shows hepatocyte contribution to cfDNA increased to 77.9%, compared to 4.2% in non-treated healthy mice (Fig. 4g, Additional File 10: Figure S7).

Analysis cfDNA in patients with APAP overdose
To demonstrate potential applicability of our findings to APAP overdose in humans, we measured the total amount of cfDNA and protein liver function biomarkers in the serum of healthy volunteers (n = 11) and APAP overdose patients (n = 8), a subset of which (n = 4) were not exhibiting clinically apparent liver injury based on serum ALT levels (Additional File 11: Table S4). On average, the concentration of cfDNA in the APAP overdose patients increased by ~126-fold (Fig. 5a). In patients with clinically apparent liver injury (high ALT), total cfDNA increased by ~234-fold, whereas patients without clinically apparent liver injury (normal ALT) demonstrated mean total cfDNA increase of ~18-fold compared to healthy volunteers (Fig. 5a). The increase in total cfDNA following APAP overdose in patients was consistent with the increase in cfDNA following APAP in C57BL/6 and hepatocyte-specific knockout mice, indicating the potential of analysis of cfDNA as a clinical biomarker in APAP overdose.

To further assess the utility of cfDNA as a clinical biomarker, we compared the serum cfDNA concentration with other conventional biomarkers of liver function. Total cfDNA was higher in all patients with APAP overdose than in healthy volunteers, although two samples, one from an overdose patient with normal ALT (cfDNA = 192.87) and one healthy volunteer (cfDNA = 188.17) showed similar cfDNA concentrations (Fig. 5b). Total concentration of cfDNA also correlated with levels of glutamate dehydrogenase (GLDH), a novel APAP overdose biomarker that measures mitochondrial damage (Spearman correlation 0.85, p-value < 0.01) with the (Fig. 5c). Analysis of paired serum samples from three APAP overdose patients before and after treatment with NAC showed a decrease in total cfDNA concentration after treatment. The decrease of total cfDNA was consistent with the decrease in serum ALT levels, indicating the potential utility of total cfDNA to monitor the efficacy of treatment in APAP overdose patients (Additional File 12: Table S5).
Specific analysis of liver contributions to the cfDNA pool, measured by ddPCR, showed the percentage of liver-specific cfDNA fragments increased by ~175-fold in patients with clinically apparent liver injury compared to healthy volunteers, but no increase in liver-specific cfDNA was observed in overdose patients without clinically apparent liver injury (normal ALT) (Fig. 5d, e). Although GLDH levels were increased in APAP overdose patient with normal ALT, analysis of liver-specific cfDNA indicated that the cfDNA did not originate from liver tissue (Fig. 5f).

Discussion
Our study demonstrates the utility of tissue-specific knockout mouse models as a platform to examine the tissue origins of cfDNA. Here, we present the first absolute, direct measurement of the tissue origins of cfDNA in healthy mice, as well as post-APAP overdose. Our data show that hematopoietic cells, including myeloid, lymphoid and erythroid cells, are the major components of cfDNA in the healthy state, with a minor contribution from liver and no detectable contribution from cardiomyocytes and skeletal muscle cells. Our results show concordance with other indirect methods, such as nucleosomal profiling and methylation analysis, that have assessed the tissue origins of cfDNA [7, 21–23], although these studies show considerable variation in the estimates of tissue origin, which may in part be due to the indirect or relative measurement methods [24]. Analysis of cfDNA using tissue-specific knockout mice had previously been performed to explore the utility of total cfDNA and circulating tumour DNA (ctDNA) as an early-stage biomarker of cancer [38]. Measurement of tissue origins of cfDNA in knockout mouse models is direct and specific for the tissue of interest and benefits from the ability to control external variables, further reducing sample variability. This experimental design may therefore be more accurate and less error-prone than indirect relative methods. The utilisation of knockout mouse models can be extended to study the tissue origins of cfDNA from not only haematopoietic cells, but also other cells of interest depending on the availability of Cre-regulated promoter.

We also demonstrate the applicability of this model system in a pathological scenario. The total concentration of cfDNA and the hepatocyte-derived fraction of
cfDNA increased substantially after APAP-induced liver injury in mice. This large increase in total cfDNA and hepatocyte-specific cfDNA after APAP overdose demonstrate the sensitivity of the model system for detecting perturbations in the origins of cfDNA arising from external stimuli. The study is the first to show the contribution of a specific tissue to the pool of cfDNA using tissue-specific knockout mice, thereby serving as a generic proof of concept for investigations of the cellular origins of cfDNA in other physiological and pathological conditions. This may include exercise, infection, autoimmunity, trauma, myocardial infarction and transplantation as well as in studies of development and ageing. Analysis of the tissue origins of cfDNA has the potential to be applied to any condition associated with cell death or loss of nuclear DNA, into plasma or other bodily fluids, such as urine, saliva or cerebrospinal fluid.

APAP overdose is the most common cause of acute liver failure in the USA and Europe [39]. Previous studies have suggested the utility of cfDNA as a clinical biomarker of cell death in a range of clinical conditions [15, 18], but cfDNA has not previously been studied as a biomarker of liver damage in APAP overdose. We found that total concentration of cfDNA robustly distinguished APAP overdose patients from healthy volunteers. Further, total concentration of cfDNA distinguished APAP overdose patients before and after treatment with NAC, with a marked fall after NAC treatment. These results suggest that total cfDNA concentration may reflect exposure to APAP. In overdose patients with raised ALT, the increase in cfDNA concentration was greater than in those with normal ALT, although all overdose patients had a higher cfDNA concentration than healthy volunteers. However, whilst there was also a clear increase in the proportion of cfDNA that originated from liver in overdose patients with raised ALT concentrations, the proportion of liver-specific cfDNA was not increased in overdose patients with normal ALT. This contrasts with our observation of increased GLDH in all overdose patients, both those with raised and normal ALT. Previous studies have proposed GLDH as a marker of liver damage in APAP overdose [40], but these data suggest that

---

**Fig. 4** The tissue origins of cfDNA following APAP overdose in mouse models. Barplots of concentration of blood biomarkers from APAP-injected hepatocyte-specific knockout mice (n = 4) and saline-treated negative control (n = 10, pooled): a total cell-free DNA, b bilirubin, c AST, d ALT, e albumin. Data are shown as mean ± standard error. f H&E staining of liver tissues from an APAP-injected hepatocyte-specific knockout mice vs saline-treated negative control showing acute zone 3 coagulative necrosis typical of APAP hepatotoxicity. g Comparison of hepatocyte cell contribution in healthy mice vs post APAP overdose (n = 4).
in APAP patients with normal ALT, the rise in total cfDNA and GLDH was not liver-derived and may have been due to damage of tissues other than the liver. Given that serum GLDH is a measure of mitochondrial damage [41] and that GLDH is expressed heterogeneously across mammalian tissues [42], the increase in GLDH and cfDNA in patients without clinically overt liver injury may reflect release of cfDNA from other tissues, for which further pre-clinical and clinical work is indicated to establish the source.

Despite the novel approach of absolute and direct measurement of cfDNA, our study is limited by issues that are widely acknowledged in the field of cfDNA research [43]. Firstly, low cfDNA concentration and low plasma volume of mice means pooling of cfDNA from at least 10 mice was necessary to obtain sufficient material for ddPCR assay measurement. In addition, haemolysis and contamination of large cfDNA fragments that arises from lysis of blood cells during sample processing may have led to an overestimation of the fraction of cfDNA derived from white blood cells. Finally, the contribution of cells measured in this study is dependent upon the activity and specificity of Cre-recombinase, which varies between knockout lines.

Prior to wider application of cfDNA assays in the clinic, it will be important to understand the sources of variability in cfDNA concentrations in healthy subjects and the origins of cfDNA in the presence of physiological stimuli such as exercise and common disorders (e.g. upper respiratory infection). Whilst studies in humans can give indirect measures of tissue origins of cfDNA, optimal assay design and interpretation will require greater understanding of the effects of developmental stage and physiological and pathological state, as well as the mechanism of release for injured or dying tissue. These factors are difficult to study in humans and the model system reported here may yield insights that are of value for clinical assay development. For the specific clinical scenario studied here, APAP overdose, in which current patient stratification is acknowledged to be sub-optimal [44], follow-up studies in larger numbers will be needed for validation and formal assessment of sensitivity, specificity and predictive power.

Conclusions
Absolute measurement of the tissue origins of cfDNA in the healthy state showed major contributions from hematopoietic cells, minor contributions from hepatocytes, and no detectable contribution from cardiac and skeletal muscle. The analysis of cfDNA is a candidate biomarker for stratification of APAP overdose patients.
Additional file 1: Figure S1. A schematic representation of the overall strategy for absolute quantitation of the tissue origins of cell-free DNA. Description of data: A conditional knockout is generated in the tissue of interest (e.g. liver) for each mouse model, containing a tissue/cell-specific Cre recombinase and the reporter gene floxed mT/mG. Cre recombinase occurs in target cells/tissues, causing deletion of a loxP site and the mT gene, leaving one loxP site in the DNA (1lox), and enabling the expression of the mG gene as opposed to other tissues in the body that contain two loxP sites (2lox). Histology and DNA analysis are performed in mouse tissues to confirm Cre recombination. Cell-free DNA, containing a mixture of 1lox and 2lox alleles released by various tissues through normal tissue turnover, can be extracted and analysed to reveal absolute contribution of cell-type/tissue of interest.

Additional file 2: Figure S2. Body weight measurements from different mouse lines at 10–12 week old. Description of data: Body weight of mice (n > 10) ranges between 2.06 and 3.19 g. Tissue knockout mouse lines showed similar body weight to non-knockout control (no Cre).

Additional file 3: Table S1. Oligonucleotides for amplification of 1lox and 2lox mT/mG gene. Description of data: 1lox assay consisted of mTmGF1, mTmGR and mTmGP. 2lox assay consisted of mTmGF2, mTmGR, mTmGP. FAM: 6-carboxyfluorescein; BHQ: black hole quencher. Amplicon length for 1lox and 2lox assays are 124 bp. (XLS 25 kb)

Additional file 4 Table S2. Primer pairs and probes for amplification of liver and non-liver DNA fragments using methylation ddPCR. Description of data: Amplification of liver and non-liver DNA fragments was performed as previously described [37].

Additional file 5: Figure S3. Specificity of Cre recombination across 16 mouse tissues in four knockout lines. Description of data: Knockout lines from top to bottom: myeloid, lymphoid, erythroid and striated muscle.

Additional file 6: Figure S4. Total amount of cfDNA extracted from a single mouse, and pools of 5, and 10 C57BL/6 mice. Description of data: Total amount of cfDNA from a pool of 10 mice provided sufficient cfDNA input for at least duplicate measurements using ddPCR (20 ng for a single measurement of 1lox and 2lox alleles).

Additional file 7: Table S3. Measurements of the tissue origins of cfDNA in the healthy state between three studies. Description of data: A comparison of tissue contributions between the present study with 2 other studies in human based on tissue-specific methylation pattern by Sun et al. [21] and Moss et al. [23].

Additional file 8: Figure S5. The effect of APAP on biomarkers at different timepoints in C57BL/6 mice. Description of data: The concentration of cfDNA (A), concentration of alanine aminotransferase (B) and aspartate aminotransferase (C) peaked at 8 h following APAP dosing and decreased after 24 and 48 h. The levels of albumin (D) and bilirubin (E) were unaffected by APAP dosing, indicating the absence of overt liver failure. Histological analysis (F) showed that liver damage (acute zone 3 coagulative necrosis typical of APAP hepatotoxicity) was most severe at 24 h following APAP compared to other time points.

Additional file 9: Figure S6. Fragment size of cfDNA following APAP overdose in four mice showed a majority contribution of mononucleosomal DNA (~150 bp).

Additional file 10: Figure S7. The effect of intraperitoneal injection on the tissue origins of cfDNA. Description of data: The increase of hepatocyte contribution in the analysis of the tissue origins of cfDNA 8h after APAP dosing in hepatocyte-specific knockout mice was not caused by intraperitoneal injection, as shown by a decrease of tissue contribution in mice injected with saline.

Additional file 11: Table S4. Measurements of serum biomarkers from APAP overdose patients and healthy volunteers. Description of data: Normal range for serum biomarker [45, 46]. Bilirubin (2–17 μmol/l), ALT (0–45 IU/l), AST (0–35 IU/l), ALP (30–120 IU/l), ALB/Albumin (40–60 g/l), GLDH (1–10 IU/l).

Additional file 12: Table S5. Comparison of biomarkers in APAP overdose patients before and after treatment with NAC. Description of data: Total cfDNA was measured using a single-locus qPCR of the human beta-actin gene (ACTB). The normal range for serum ALT is 0–45 IU/l.

Abbreviations
ACTB: beta-actin; ALB: Albumin; ALT: Alanine aminotransferase; CRUK: Cancer Research UK; EpoR: Erythropoietin receptor; FAM: 6-carboxyfluorescein; GLDH: Glutamate dehydrogenase; GLP: Green fluorescent protein; GDH: Glutamic dehydrogenase; H&E: Hematoxylin and eosin; IP: Intraperitoneal; mG: Cell membrane-localised enhanced green fluorescent protein; mT: Cell membrane-localised tdTomato; mT/mG: Cre recombinase and the reporter gene floxed GFP; mTmGF1, mTmGR and mTmGP: 1lox assay consisted of mTmGF1, mTmGR and mTmGP. 2lox assay consisted of mTmGF2, mTmGR, mTmGP. FAM: 6-carboxyfluorescein; BHQ: black hole quencher. Amplicon length for 1lox and 2lox assays are 124 bp.

Acknowledgements
We thank Prof. Mary Porteous and the South East Scotland Genetics service for access to the Biobank droplet-digital PCR system, Prof. Stuart Orkin of Cooperative Centers of Excellence in Hematology (CCEHi) core laboratory (supported by National Institute of Diabetes and Digestive and Kidney Diseases), Boston Children’s Hospital, for his generous donation of EpoR Cre mice, and members of our laboratory for critical review of the manuscript.

Authors’ contributions
DL conceived and designed the study, performed experiments and analyses, and wrote the manuscript. FS and PjSL designed the study and performed experiments and analyses. ER and JC performed experiments and analyses. MAJ performed analyses. SJF and JWD designed the study, performed analyses, wrote the manuscript and provided funding. All authors read and approved the final manuscript.

Funding
This work was funded by Cancer Research UK (CRUK) Edinburgh Centre C157/A25140 and an Early Detection Committee Project Award C22524/ A26254 to TJA. DL was funded by the Indonesia Endowment Fund for Education as a PhD student.

Availability of data and materials
All data supporting the conclusion of this article are included in this published article and its additional files.

Ethics approval and consent to participate
Animal model work in this study was carried out in line with UK Home Office project licenses PPL P107041A9 and PPL 70/7847. The protocol for clinical samples was approved by the Scotland A Research Ethics Committee, UK (ref no 10/MRE00/20). Written informed consent was obtained from all patients included in the study. All patients were 16 years old or above.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Centre for Genomic and Experimental Medicine, Medical Research Council Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK. 2Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK. 3Division of Pathology, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK. 4Pharmacology, Toxicology and Therapeutics, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
References

1. Mandel P, Metens P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil. 1948;142:241–3.
2. Bumham P, Dadhania D, Heyang M, Chen F, Westblade LF, Suthanthiran M, et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat Commun. 2018;9:2412. https://doi.org/10.1038/s41467-018-04745-0.
3. Peng M, Chen C, Hulbert A, Brock MV, Yu F. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8:95162–79.
4. Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ. The diverse origins of circulating-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev Camb Philos Soc. 2018;93:1649–83.
5. Jiang P, Lo YMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. 2016;32:670–81.
6. Thiery AR, El Messaoudi S, Gahan PB, Ander P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2015;34:376–92.
7. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164:57–68.
8. Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.
9. Chitty LS, Lo YMD. Noninvasive prenatal screening for genetic diseases involving massively parallel sequencing of maternal plasma DNA. Cold Spring Harb Perspect Med. 2015;5:a023085.
10. Renga B. Non-invasive prenatal diagnosis of fetal aneuploidy using cell-free fetal DNA. Eur J Obstet Gynecol Reprod Biol. 2018;225:5–8.
11. Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, et al. CancerLocator: non-invasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112:E5503–12.
12. Lam WJ, Gai W, Sun K, Wong RY, Chan RWY, Jiang P, et al. DNA of erythroid origin is present in human plasma and informs the types of anemia. Clin Chem. 2017;63:1614–23.
13. Moss J, Magenheim J, Neiman D, Zemmour H, Loyer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9:5068.
14. Heitzer E, Hauge IS, Roberts CE, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88.
15. Muzumdar MD, Taic B, Miyamiichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.
16. Claussen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysoMice mice. Transgenic Res. 1999;8:265–77.
17. de Boer J, Williams A, Skavdiss G, Barker N, Colles M, Tolaini M, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol. 2003;33:314–25.
18. Jiao K, Kulesha H, Tompkins K, Zhou Y, Batts L, Baldwin HS, et al. An essential role of Bmp4 in the atrioventricular septation of the mouse heart. Genes Dev. 2003;17:2362–7.
19. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274:305–15.
20. Bruning JC, Michael MD, Winnay JN, Hayashi T, Honsch D, Acioli D, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998;2:559–69.
21. Heinrich AC, Pelanda R, Klingmuller U. A mouse model for visualization and conditional mutations in the erythrocyte lineage. Blood. 2004;104:659–66.
22. Bateman DM, Dear JW, Thanacoody KR, Thomas SHL, Eddleston M, Sandillians EA, et al. Reduction of adverse effects from intravenous acylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383:697–704.
23. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38:6519–75.
24. Li P, Ning J, Luo X, Du H, Zhang Q, Zhou G, et al. New method to preserve the original proportion and integrity of urinary cell-free DNA. J Clin Lab Anal. 2018;32:e22668.
25. Weis B, Schmidt J, Lyko F, Linhart HG. Analysis of conditional gene deletion using probe based real-time PCR. BMC Biotechnol. 2010;10:75.
26. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3–new capabilities and interfaces. Nucleic Acids Res. 2012;40:e15.
27. Gai W, Li J, Lam WKJ, Sun K, Jiang P, Chan AWH, et al. Liver- and colorectal-specific DNA methylation markers in plasma for investigation of colorectal cancers with or without liver metastases. Clin Chem. 2018;64:1239–49.
28. Rahkit CP, Trigg RM, Le Querrec T, Kelly M, Shaw JA, Pritchard C, et al. Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Dis Model Mech. 2019;12:2266–75.
29. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38:6519–75.
30. Li P, Ning J, Luo X, Du H, Zhang Q, Zhou G, et al. New method to preserve the original proportion and integrity of urinary cell-free DNA. J Clin Lab Anal. 2018;32:e22668.
31. Weis B, Schmidt J, Lyko F, Linhart HG. Analysis of conditional gene deletion using probe based real-time PCR. BMC Biotechnol. 2010;10:75.
32. Gai W, Li J, Lam WKJ, Sun K, Jiang P, Chan AWH, et al. Liver- and colorectal-specific DNA methylation markers in plasma for investigation of colorectal cancers with or without liver metastases. Clin Chem. 2018;64:1239–49.
33. Rahkit CP, Trigg RM, Le Querrec T, Kelly M, Shaw JA, Pritchard C, et al. Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Dis Model Mech. 2019;12:2266–75.
34. Bernal W, Weldon J. Acute liver failure. N Engl J Med. 2013;369:2525–34. https://doi.org/10.1056/NEJMoa1208937.
35. Antoine DJ, Dear JW, Lewis PS, Pratt V, Coyle J, Masson M, et al. Mechanistic biomarkers provide early and sensitive detection of acetylsalicylic acid-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58:777–87.
36. McNeill MR, Sharpe MR, Williams CD, Taha M, Cury SC, Jaeschke H. The mechanism underlying acetylsalicylic acid-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012;122:1574–83.
37. Sapanli C, Kotzaman D, Petkari Z, Drakos E, Polatakis A. Expression of human GLUD1 and GLUD2 glutamate dehydrogenases in steroid producing tissues. Mol Cell Endocrinol. 2015;415:1–11.
38. Ribbens B, Tsai DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson S, Hodgkin C, et al. Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients. J Mol Diagn. 2018;20:883–92.
39. Dear JW, Clarke J, Francis B, Allen L, Wraight J, Shen J, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers.
results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3:104–13.
45. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. 2003;79:307–12. https://doi.org/10.1136/pmj.79.932.307.
46. Schomaker S, Warner R, Bock J, Johnson K, Potter D, Van Winkle J, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci. 2013;132:276–83.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.